Plasma Proteome-Based Test for First-Line Treatment Selection in Metastatic Non-Small Cell Lung Cancer.
Petros ChristopoulosMichal HarelKimberly McGregorYehuda BrodyIgor PuzanovJair BarYehonatan ElonItamar SelaBen YellinCoren LahavShani RavehAnat Reiner BenaimNiels ReinmuthHovav NechushtanDavid FarrugiaErnesto Bustinza-LinaresYanyan LouRaya LeibowitzIris KamerAlona Zer KuchMor MoskovitzAdva Levy-BardaIna KochMichal LotemRivka KatzenelsonAbed AgbaryaGillian PriceHelen CheleyMahmoud Abu-AmnaTom GeldartMaya GottfriedElla TepperAndreas PolychronisIdo WolfAdam P DickerDavid P CarboneDavid R GandaraPublished in: JCO precision oncology (2024)
Plasma proteome-based testing of individual patients, in combination with standard PD-L1 testing, distinguishes patient subsets with distinct differences in outcomes from PD-1/PD-L1 inhibitor-based therapies. These data suggest that this approach can improve the precision of first-line treatment for metastatic NSCLC.